Huakang Biomedical Holdings Company Limited (8622.HK)
HKD 0.18
(1.67%)
HKD 0.18
(1.67%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 65.31 Million CNY | -1.64% |
| 2022 | 66.4 Million CNY | -0.98% |
| 2021 | 67.06 Million CNY | -7.76% |
| 2020 | 72.7 Million CNY | -7.64% |
| 2019 | 78.71 Million CNY | -5.66% |
| 2018 | 83.43 Million CNY | 72.31% |
| 2017 | 48.42 Million CNY | 29.3% |
| 2016 | 37.44 Million CNY | 36.23% |
| 2015 | 27.48 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 66.78 Million CNY | 2.25% |
| 2024 Q2 | 66.78 Million CNY | 0.0% |
| 2023 Q4 | 65.31 Million CNY | 0.0% |
| 2023 Q2 | 64.12 Million CNY | 0.0% |
| 2023 Q3 | - CNY | -100.0% |
| 2023 Q1 | - CNY | -100.0% |
| 2023 FY | 65.31 Million CNY | -1.64% |
| 2022 Q1 | - CNY | -100.0% |
| 2022 FY | 66.4 Million CNY | -0.98% |
| 2022 Q4 | 66.4 Million CNY | 0.0% |
| 2022 Q3 | - CNY | -100.0% |
| 2022 Q2 | 64.35 Million CNY | 0.0% |
| 2021 Q2 | 69.82 Million CNY | 0.0% |
| 2021 Q1 | - CNY | -100.0% |
| 2021 FY | 67.06 Million CNY | -7.76% |
| 2021 Q4 | 67.06 Million CNY | 0.0% |
| 2020 Q4 | 72.7 Million CNY | 0.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 FY | 72.7 Million CNY | -7.64% |
| 2020 Q2 | 73.1 Million CNY | 0.0% |
| 2019 Q2 | 76.5 Million CNY | 0.0% |
| 2019 Q4 | 78.71 Million CNY | 0.0% |
| 2019 FY | 78.71 Million CNY | -5.66% |
| 2019 Q1 | - CNY | -100.0% |
| 2018 Q1 | - CNY | 0.0% |
| 2018 FY | 83.43 Million CNY | 72.31% |
| 2018 Q4 | 83.43 Million CNY | 0.0% |
| 2018 Q2 | 49.74 Million CNY | 0.0% |
| 2017 FY | 48.42 Million CNY | 29.3% |
| 2016 FY | 37.44 Million CNY | 36.23% |
| 2015 FY | 27.48 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 907.46 Million HKD | 92.802% |
| Grand Pharmaceutical Group Limited | 22.51 Billion HKD | 99.71% |
| Extrawell Pharmaceutical Holdings Limited | 1.28 Billion HKD | 94.926% |
| Wai Yuen Tong Medicine Holdings Limited | 2.09 Billion HKD | 96.883% |
| Qianhai Health Holdings Limited | 478.11 Million HKD | 86.339% |
| Lee's Pharmaceutical Holdings Limited | 2.89 Billion HKD | 97.74% |
| Essex Bio-Technology Limited | 2.82 Billion HKD | 97.69% |
| Tongfang Kontafarma Holdings Limited | 1.72 Billion HKD | 96.219% |
| PuraPharm Corporation Limited | 843.96 Million HKD | 92.261% |
| SSY Group Limited | 11.96 Billion HKD | 99.454% |
| JBM (Healthcare) Limited | 1.38 Billion HKD | 95.297% |
| Jacobson Pharma Corporation Limited | 3.48 Billion HKD | 98.127% |
| China Resources Pharmaceutical Group Limited | 271.69 Billion HKD | 99.976% |